Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clotrimazole + betamethasone dipropionate + zinc oxide is a **topical small-molecule combination product** consisting of clotrimazole, an imidazole antifungal that inhibits fungal ergosterol synthesis and disrupts fungal cell-membrane formation; betamethasone dipropionate, a potent corticosteroid that activates glucocorticoid receptors to suppress local inflammation, pruritus, and erythema; and zinc oxide, a skin protectant used as a barrier paste. The combination is marketed as kit products including **Clobezin** and **DermacinRx Therazole Pak** and is used for the topical treatment of symptomatic inflammatory **tinea pedis, tinea cruris, and tinea corporis** caused by susceptible dermatophytes in patients 17 years and older, while the zinc oxide component provides protective barrier support to irritated skin. The drug is a marketed pharmaceutical formulation rather than a novel molecular entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotrimazole + betamethasone dipropionate + zinc oxide.